Abstract:Abstract A well-established preclinical model of pancreatic cancer needs to be established to facilitate research on new therapeutic targets. Recently established animal models of pancreatic cancer, including patient-derived tumor models and organoid models, are used for pre-clinical drug testing and biomarker discovery. These models have useful characteristics over conventional xenograft mouse models based on cell lines in preclinical studies, but still cannot accurately predict the clinical outcomes of new treatments and have not yet been broadly implemented in research. We employed pancreatic cancer organoid culture methods using the pancreatic cancer cell line S2-013, and performed pathological and immunohistochemical analyses to characterize tumor xenografts obtained from a mouse model implanted with S2-013 cell line-derived organoids. Serum levels of the pancreatic cancer tumor marker CA19-9 were measured by ELISA. We generated human pancreatic cancer organoids using a co-culture of S2-013 cells, human endothelial cells derived from human umbilical vein endothelial cells, and human mesenchymal stem cells, and established a mouse model with subcutaneously transplanted human pancreatic cancer organoids (S2-013-organoid model). Although blood clotting crater-like formation developed in the middle of subcutaneous xenografts in the S2-013-conventional model, created by subcutaneously injecting S2-013 cells into the right flank of nude mice, the size of xenografts in the S2-013-organoid model gradually increased without crater-like formation. Importantly, tumor xenografts obtained from the S2-013-organoid model exhibited a clinical human pancreatic cancer tissue-like cellular morphology, tissue architecture, and polarity, and actively formed cancer stroma containing mature blood vessels with the high expression of the vascular tight junction marker CD31. In subcutaneous xenografts of S2-013-conventional mice, no blood vessel density or widely expanding areas of necrotic regions were present. Consequently, serum levels of CA19-9 in the S2-013-organoid model correlated with tumor volumes. In addition, epithelial–mesenchymal transition, the conversion of epithelial cells to the mesenchymal phenotype, was observed in tumor xenografts of the S2-013-organoid model. The S2-013-organoid model provides tumor xenografts consisting of clinical human pancreatic cancer-like tissue formation with the effective development of vascularized stroma, and may be valuable for facilitating studies on pre-clinical drug testing and biomarker discovery.

Establishment and characterization of a patient-derived orthotopic xenograft ( PDOX) model of pancreatic cancer

Establishing A Patient-Derived Colorectal Cancer Xenograft Model For Translational Research

Differences in Nanoparticle Uptake in Transplanted and Autochthonous Models of Pancreatic Cancer

Establishment of a Patient-Derived Orthotopic Xenograft (PDOX) Model of HER-2-Positive Cervical Cancer Expressing the Clinical Metastatic Pattern

Characteristics and research strategies of patient-derived orthotopic xenograft models

Establishment of Orthotopic Transplantation Nude Mouse Model with Pancreatic Cancer Celllines CFPAC

A preliminary discussion on establishment of patient-derived tumor xenograft (PDTX) model and testing of pharmacodynamics

Abstract 1204: Establishment of a patient-derived orthotopic xenograft (PDOX) model of patient cervical cancer

Establishment of a novel human cell line retaining the characteristics of the original pancreatic adenocarcinoma, and evaluation of MEK as a therapeutic target

Application of near infrared fluorescent dye in the study of patient-derived gastric cancer xenograft nude mouse models

A Preliminary Study on the Establishment of the PDTX Model

Establishment of a PDTT xenograft model of gastric carcinoma and its application in personalized therapeutic regimen selection.

Establishment of Pancreatic Cancer Patient-Derived Xenograft Models and Comparison of the Differences among the Generations.

Establishment and Characterization of Patient-Derived Tumor Xenograft Using Gastroscopic Biopsies in Gastric Cancer

Establishment of a mouse model of pancreatic cancer using human pancreatic cancer cell line S2-013-derived organoid

Establishment of Three Human Pancreatic Cancer Orthotopic Xenograft Nude Mice Models and Serum Metabolomics

Patient-derived xenograft model engraftment predicts poor prognosis after surgery in patients with pancreatic cancer

Patient-derived Xenografts: a Valuable Platform for Clinical and Preclinical Research in Pancreatic Cancer.

Metastatic Recurrence in a Pancreatic Cancer Patient Derived Orthotopic Xenograft (PDOX) Nude Mouse Model is Inhibited by Neoadjuvant Chemotherapy in Combination with Fluorescence-Guided Surgery with an Anti-CA 19-9-conjugated Fluorophore

Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers

Oncological and genetic factors impacting PDX model construction with NSG mice in pancreatic cancer